226 related articles for article (PubMed ID: 23916502)
1. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.
Gelb AF; Tashkin DP; Make BJ; Zhong X; Garcia Gil E; Caracta C;
Respir Med; 2013 Dec; 107(12):1957-65. PubMed ID: 23916502
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
4. One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD.
D'Urzo A; Kerwin E; Rennard S; He T; Gil EG; Caracta C
COPD; 2013 Aug; 10(4):500-10. PubMed ID: 23679347
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
Donohue JF; Soong W; Wu X; Shrestha P; Lei A
Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
[TBL] [Abstract][Full Text] [Related]
7. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.
Jones P
Adv Ther; 2013 Apr; 30(4):354-68. PubMed ID: 23553509
[TBL] [Abstract][Full Text] [Related]
8. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
Rennard SI; Scanlon PD; Ferguson GT; Rekeda L; Maurer BT; Garcia Gil E; Caracta CF
Clin Drug Investig; 2013 Dec; 33(12):893-904. PubMed ID: 24085591
[TBL] [Abstract][Full Text] [Related]
9. Improvements in patient-reported outcomes: A prospective, non-interventional study with aclidinium bromide for treatment of COPD.
Marth K; Schuller E; Pohl W
Respir Med; 2015 May; 109(5):616-24. PubMed ID: 25796962
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
Jones PW; Singh D; Bateman ED; Agusti A; Lamarca R; de Miquel G; Segarra R; Caracta C; Garcia Gil E
Eur Respir J; 2012 Oct; 40(4):830-6. PubMed ID: 22441743
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
Lasseter K; Dilzer S; Jansat JM; Garcia Gil E; Caracta CF; Ortiz S
Pulm Pharmacol Ther; 2012 Apr; 25(2):193-9. PubMed ID: 22366196
[TBL] [Abstract][Full Text] [Related]
12. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.
Woods JA; Nealy KL; Barrons RW
Ann Pharmacother; 2013; 47(7-8):1017-28. PubMed ID: 23737515
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
Jones PW; Rennard SI; Agusti A; Chanez P; Magnussen H; Fabbri L; Donohue JF; Bateman ED; Gross NJ; Lamarca R; Caracta C; Gil EG
Respir Res; 2011 Apr; 12(1):55. PubMed ID: 21518460
[TBL] [Abstract][Full Text] [Related]
14. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.
Singh D; Magnussen H; Kirsten A; Mindt S; Caracta C; Seoane B; Jarreta D; Garcia Gil E
Pulm Pharmacol Ther; 2012 Jun; 25(3):248-53. PubMed ID: 22497752
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.
Lee SH; Lee J; Yoo KH; Uh ST; Park MJ; Lee SY; Kim JY; Kim DK; Kim SJ; Lee KH; Yoo CG
Respirology; 2015 Nov; 20(8):1222-8. PubMed ID: 26370136
[TBL] [Abstract][Full Text] [Related]
16. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
Maltais F; Milot J
Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544
[TBL] [Abstract][Full Text] [Related]
17. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease.
D'Urzo A; Rennard S; Kerwin E; Donohue JF; Lei A; Molins E; Leselbaum A
Respir Med; 2017 Apr; 125():39-48. PubMed ID: 28340861
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
19. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.
Joos GF; Schelfhout VJ; Pauwels RA; Kanniess F; Magnussen H; Lamarca R; Jansat JM; Garcia Gil E
Respir Med; 2010 Jun; 104(6):865-72. PubMed ID: 20044242
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.
Jansat JM; Lamarca R; de Miquel G; Schrödter A; Miletzki B; Gurniak M
J Clin Pharmacol; 2009 Oct; 49(10):1239-46. PubMed ID: 19592595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
